GB202108779D0 - Si-at therapeutic/diagnostic compounds - Google Patents

Si-at therapeutic/diagnostic compounds

Info

Publication number
GB202108779D0
GB202108779D0 GBGB2108779.6A GB202108779A GB202108779D0 GB 202108779 D0 GB202108779 D0 GB 202108779D0 GB 202108779 A GB202108779 A GB 202108779A GB 202108779 D0 GB202108779 D0 GB 202108779D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic
diagnostic compounds
diagnostic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108779.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blue Earth Diagnostics Ltd
Original Assignee
Blue Earth Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blue Earth Diagnostics Ltd filed Critical Blue Earth Diagnostics Ltd
Priority to GBGB2108779.6A priority Critical patent/GB202108779D0/en
Publication of GB202108779D0 publication Critical patent/GB202108779D0/en
Ceased legal-status Critical Current

Links

GBGB2108779.6A 2021-06-18 2021-06-18 Si-at therapeutic/diagnostic compounds Ceased GB202108779D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2108779.6A GB202108779D0 (en) 2021-06-18 2021-06-18 Si-at therapeutic/diagnostic compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108779.6A GB202108779D0 (en) 2021-06-18 2021-06-18 Si-at therapeutic/diagnostic compounds

Publications (1)

Publication Number Publication Date
GB202108779D0 true GB202108779D0 (en) 2021-08-04

Family

ID=77050405

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108779.6A Ceased GB202108779D0 (en) 2021-06-18 2021-06-18 Si-at therapeutic/diagnostic compounds

Country Status (1)

Country Link
GB (1) GB202108779D0 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065145A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University Psma targeted reversed carbamates and methods of use thereof
WO2017070482A2 (en) 2015-10-22 2017-04-27 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
WO2019020831A1 (en) 2017-07-28 2019-01-31 Technische Universität München Dual mode radiotracer and -therapeutics
WO2019157037A1 (en) 2018-02-06 2019-08-15 The Johns Hopkins University Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
WO2020028323A1 (en) 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
WO2020157184A1 (en) 2019-01-30 2020-08-06 Technische Universität München Cancer diagnostic imaging agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065145A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University Psma targeted reversed carbamates and methods of use thereof
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
WO2017070482A2 (en) 2015-10-22 2017-04-27 The Johns Hopkins University Psma targeted radiohalogenated ureas for cancer radiotherapy
WO2019020831A1 (en) 2017-07-28 2019-01-31 Technische Universität München Dual mode radiotracer and -therapeutics
WO2019157037A1 (en) 2018-02-06 2019-08-15 The Johns Hopkins University Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
WO2020028323A1 (en) 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
WO2020157184A1 (en) 2019-01-30 2020-08-06 Technische Universität München Cancer diagnostic imaging agents

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
AFSHAR-OROMIEH ET AL., EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 42, 2015, pages 197 - 209
BARINKA ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, 2008, pages 7737 - 7743
BENESOVA ET AL., JOURNAL OF NUCLEAR MEDICINE, vol. 56, 2015, pages 914 - 920
BERNARD-GAUTHIER ET AL., BIOMED RES INT, vol. 2014, 2014, pages 454503
BRYN ET AL.: "Solid-State Chemistry of Drugs", 1999, SSCI, INC OF WEST LAFAYETTE
DIETLEIN ET AL., MOLECULAR IMAGING AND BIOLOGY, vol. 17, 2015, pages 575 - 584
EDER ET AL., BIOCONJUGATE CHEMISTRY, vol. 23, 2012, pages 688 - 697
GIESEL ET AL., EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 44, 2017, pages 678 - 688
GIESEL, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 43, 2016, pages 1929 - 1930
GUERARD, F ET AL., CANCER BIOTHER. RADIOPHARM., vol. 28, no. 1, February 2013 (2013-02-01), pages 1 - 20
KIESS ET AL., THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 59, 2015, pages 241
LINDNER ET AL., BIOCONJUGATE CHEMISTRY, vol. 25, 2014, pages 738 - 749
LINDNER S ET AL., BIOCONJUG CHEM, vol. 25, no. 4, 16 April 2014 (2014-04-16), pages 738 - 49
LIU ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, 2011, pages 7013 - 7016
MACHULKIN ET AL., JOURNAL OF DRUG TARGETING, 2016, pages 1 - 15
MAURER ET AL., NATURE REVIEWS UROLOGY, 2016
NIEDERMOSER S ET AL., J NUCL MED, vol. 56, no. 7, July 2015 (2015-07-01), pages 1100 - 5
ROBU ET AL., JOURNAL OF NUCLEAR MEDICINE, vol. 116, 2016, pages 178939
ROWE ET AL., MOLECULAR IMAGING AND BIOLOGY, 2016, pages 1 - 9
ROWE ET AL., PROSTATE CANCER AND PROSTATIC DISEASES, 2016
SCHIRRMACHER E ET AL., BIOCONJUGATE CHEM., vol. 18, 2007, pages 2085 - 2089
SILVE ET AL., CLINICAL CANCER RESEARCH, vol. 3, 1997, pages 81 - 85
WANGLER C ET AL., BIOCONJUG CHEM, vol. 21, no. 12, 15 December 2010 (2010-12-15), pages 2289 - 96
WANGLER C ET AL., BIOCONJUGATE CHEM., vol. 20, no. 2, 2009, pages 317 - 321
WEINEISEN ET AL., JOURNAL OF NUCLEAR MEDICINE, vol. 55, 2014, pages 1083 - 1083
ZHANG ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, 2010, pages 12711 - 12716
ZHOU ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 4, 2005, pages 1015 - 1026

Similar Documents

Publication Publication Date Title
GB202005852D0 (en) Therapeutic compounds
EP4255276A4 (en) Medical diagnostic kit
GB202001980D0 (en) Therapeutic mentods
GB202006960D0 (en) Therapeutic
GB202205895D0 (en) New medical uses
GB202005863D0 (en) Therapeutic compounds
GB202108779D0 (en) Si-at therapeutic/diagnostic compounds
GB202012326D0 (en) Diagnostic
GB201908885D0 (en) Therapeutic compounds
IL312745A (en) Therapeutic compounds
IL309569A (en) Therapeutic compounds
GB202110728D0 (en) Therapeutic compounds
GB202103642D0 (en) Therapeutic compounds
GB202103640D0 (en) Therapeutic compounds
GB202101577D0 (en) Therapeutic compounds
GB202101574D0 (en) Therapeutic compounds
GB202016934D0 (en) Therapeutic compounds
GB202016931D0 (en) Therapeutic compounds
GB202012670D0 (en) Therapeutic compounds
GB202007931D0 (en) Therapeutic compounds
GB202007925D0 (en) Therapeutic compounds
GB202005848D0 (en) Therapeutic compounds
GB202005846D0 (en) Therapeutic compounds
GB202302445D0 (en) Therapeutic compounds
GB202217955D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)